Global T-Cell Therapy Market
T-cell is a type of white blood cell and they help to protect the body from infection and may help to fight cancer. Also, it is a part of immune system. The T-cell therapy is defined as a novel immunotherapy that helps to treat various types of cancers. These are re-engineered cells are then multiplied and infused into the body to recognize & kill cancer cells with targeted antigens on their surface.
Market Drivers
The increase in incidence of cancer as well as growing number of patients showing response failure to alternative treatments is expected to boost the global T-cell therapy market growth over the forecast period. Further, the rise in number of adults & children developing cancer is anticipated to increase the demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. For instance, as per the information provided by Cancer Research UK around 14.1 million people are suffering from cancer in 2012 across the world.
Moreover, development of new & effective therapy options to cure symptoms of the disease is another prominent factor accelerating the growth of global T-cell therapy market. For instance, in 2017, U.S. Food and Drug Administration had approved two CAR-T cell therapies known as Kymriah and Yescarta for children & adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to drive the growth of the market over the forecast period. In addition, the increase in government initiatives for improving health care infrastructure & promoting research for cell therapy in cancer is supporting the growth of global T-cell therapy market.
Market Restraints
Side effects associated with the T-cell therapy may cause cytokine release syndrome (CRS) and other neurological problems like seizures, coma, hallucinations, and delirium. These are major restraining factors which expected to hamper the global T-cell therapy market over the forecast period.
Market Segmentation
The Global T-Cell Therapy Market is segmented into Modality such as Research, and Commercialized. The research segment dominates the market with considerable market share in 2020, due to the high number of products in the clinical development phase. On the basis of therapy type, market is segmented into CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based. CAR T-cell therapy is fastest growing segment in the market. This is due to the exponential rise in the number of clinical trials for CAR-T therapies. On the basis of indication market is segmented into Hematologic Malignancies, Solid Tumors, and Others. Also, the market is segmented into end users such as Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes, and Others.
Impact of COVID-19
The COVID-19 pandemic has triggered the investment flow in deciphering the application of T-cell therapies in viral infection research. For instance, as per the study published in December 2020, demonstrated the potential of this therapy to treat high-risk COVID-19 patients. This is expected to increase the adoption of T-cell therapeutics for viral infections.
Regional Analysis
Global T-Cell Therapy Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
In terms of revenue share, the North America region is dominant in the global T-cell therapy market. Due to the rapid development and launch of new therapies for the treatment of cancer in the region. For instance, as per the information provided by Centers of Disease Control and Prevention (CDC), in 2016, around 171,000 patients with blood cancer are diagnosed each year in the Unites States. Europe is expected to be the second most prominent market, in terms of revenue, due to the increasing investment & extensive research for development of cancer therapies in the region.
Key Players
Key Players operating in the global T-cell therapy market is include Novartis AG, Amgen, Celgene Corporation, Pfizer Inc., Fate Therapeutics, Bluebird Bio Inc., TCR2 Therapeutics Inc, Sorrento Therapeutics, Gilead Sciences Inc., Merck KGaA, etc. The growing number of companies involved in the development of CAR-T therapies is expected to contribute the competitive landscape of the T-cell therapy space. As of now Novartis AG have dominated the market for T-cell therapy with new product development and innovations.
Market Taxonomy
By Modality
By Therapy Type
By Indication
By End User
By Region
Key Questions Addressed by the Report
Global T-Cell Therapy Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global T-Cell Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global T-Cell Therapy Market, By Modality
5.1 Y-o-Y Growth Comparison, By Modality
5.2 Global T-Cell Therapy Market Share Analysis, By Modality
5.3 Global T-Cell Therapy Market Size and Forecast, By Modality
5.3.1 Research
5.3.2 Commercialized
6 Global T-Cell Therapy Market, By Therapy Type
6.1 Y-o-Y Growth Comparison, By Therapy Type
6.2 Global T-Cell Therapy Market Share Analysis, By Therapy Type
6.3 Global T-Cell Therapy Market Size and Forecast, By Therapy Type
6.3.1 CAR T-cell Therapy
6.3.2 T Cell Receptor (TCR)-based
6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
7 Global T-Cell Therapy Market, By Indication
7.1 Y-o-Y Growth Comparison, By Indication
7.2 Global T-Cell Therapy Market Share Analysis, By Indication
7.3 Global T-Cell Therapy Market Size and Forecast, By Indication
7.3.1 Hematologic Malignancies
7.3.2 Solid Tumors
7.3.3 Others
8 Global T-Cell Therapy Market, By End User
8.1 Y-o-Y Growth Comparison, By End User
8.2 Global T-Cell Therapy Market Share Analysis, By End User
8.3 Global T-Cell Therapy Market Size and Forecast, By End User
8.3.1 Hospitals
8.3.2 Clinics & Ambulatory Centers
8.3.3 Cancer Research Institutes
8.3.4 Others
9Global T-Cell Therapy Market, By Region
9.1 Global T-Cell Therapy Market Share Analysis, By Region
9.2 Global T-Cell Therapy Market Share Analysis, By Region
9.3 Global T-Cell Therapy Market Size and Forecast, By Region
10 North America T-Cell Therapy Analysis and Forecast (2020 – 2030)
10.1 Introduction
10.2 North America T-Cell Therapy Product Market Share Analysis, By Modality
10.3 North America T-Cell Therapy Product Market Size and Forecast, By Therapy Type
10.4 North America T-Cell Therapy Product Market Size and Forecast, By Indication
10.5 North America T-Cell Therapy Product Market Size and Forecast, By End User
10.6 North America T-Cell Therapy Product Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11Europe T-Cell Therapy Market Analysis and Forecast (2020 – 2030)
11.1 Introduction
11.2 Europe T-Cell Therapy Product Market Share Analysis, By Modality
11.3 Europe T-Cell Therapy Product Market Size and Forecast, By Therapy Type
11.4 Europe T-Cell Therapy Product Market Size and Forecast, By Indication
11.5 Europe T-Cell Therapy Product Market Size and Forecast, By End User
11.6 Europe T-Cell Therapy Product Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.64. Rest of Europe
12Asia Pacific T-Cell Therapy Market Analysis and Forecast (2020 – 2030)
12.1 Introduction
12.2 Asia Pacific T-Cell Therapy Product Market Share Analysis, By Modality
12.3 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Therapy Type
12.4 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Indication
12.5 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By End User
12.6 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4. Rest of Asia Pacific
13Latin America T-Cell Therapy Market Analysis and Forecast (2020 – 2030)
13.1 Introduction
13.2 Latin America T-Cell Therapy Product Market Share Analysis, By Modality
13.3 Latin America T-Cell Therapy Product Market Size and Forecast, By Therapy Type
13.4 Latin America T-Cell Therapy Product Market Size and Forecast, By Indication
13.5 Latin America T-Cell Therapy Product Market Size and Forecast, By End User
13.6 Latin America T-Cell Therapy Product Market Size and Forecast, By Country
14Middle East T-Cell Therapy Market Analysis and Forecast (2020 – 2030)
14.1 Introduction
14.2 Middle East T-Cell Therapy Product Market Share Analysis, By Modality
14.3 Middle East T-Cell Therapy Product Market Size and Forecast, By Therapy Type
14.4 Middle East T-Cell Therapy Product Market Size and Forecast, By Indication
14.5 Middle East T-Cell Therapy Product Market Size and Forecast, By End User
14.6 Middle East T-Cell Therapy Product Market Size and Forecast, By Country
15Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16Company Profiles
16.1 Novartis AG
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Amgen
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Celgene Corporation
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Pfizer Inc
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Fate Therapeutics
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Bluebird Bio Inc
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 TCR2 Therapeutics Inc
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Sorrento Therapeutics
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Gilead Sciences Inc
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Merck KGaA
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
